Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
Name
Mata-Fink-2012-Engineered gp120 imm.pdf
Size
161.9 KB
Format
Adobe PDF
Checksum (MD5)
809180218c9d4b28b6bf26579ac993bd
Author(s)
Mata-Fink, Jordi
Hanson, M.
Kriegsman, Barry A.
Irvine, Darrell J.
Wittrup, Karl Dane
Date Issued
September 2012
Journal
Retrovirology
Publisher
Biomed Central Ltd.
Citation
Mata-Fink, J et al. “Engineered Gp120 Immunogens That Elicit VRC01-like Antibodies by Vaccination.” Retrovirology 9.Suppl 2 (2012): P6.
Version
Final published version
Abstract
Background: One of the great challenges for an HIV vaccine is to elicit broadly neutralizing antibodies specific for conserved epitopes from which the virus cannot easily escape. The CD4 binding site is one such epitope against which several antibodies (e.g. b12, VRC01) have been isolated. In macaques infected with SHIV, passive immunization with these CD4-directed neutralizing antibodies fails to control the virus, but prophylactic administration is highly protective. Similarly, patients who generate neutralizing antibodies over the course of an HIV infection derive no clinical benefit from them, but eliciting such antibodies prophylactically by vaccination may prevent the virus from establishing its lethal foothold.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1186/1742-4690-9-s2-p6
